Drreddys Laboratories | RDY - Selling And Administration Expenses


Drreddys Laboratories reported INR26.92B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bayer EUR 3.7B 356M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Richter Gedeon HUF 55.32B 3.03B Mar/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026